Baxter reports Q2 adjusted EPS 54c, consensus 61c

Reports Q2 revenue $2.81B, consensus $2.82B. “For the second quarter of 2025, Baxter (BAX) delivered performance in line with guidance while our employees across the globe continued advancing the company’s life-sustaining Mission and building on its vision to redefine healthcare delivery,” said Brent Shafer, chair and interim CEO. “The company is poised to enter a new chapter with the appointment of Andrew Hider as our next CEO. Andrew’s extensive experience in driving operational excellence, innovation and growth at global, diversified companies will help propel Baxter into a new era of progress and performance.”